Background: Previous epidemiologic studies of the natural course of urticaria mainly focused on chronic spontaneous urticaria and were conducted at hospitals. The natural course of new-onset urticaria in the general population is unknown. Methods: Patients with new-onset urticaria were identified from the National Health Insurance Service eNational Sample Cohort data. Patients who had at least one visit for urticaria in 2002 and 2003 were excluded and the study cohort consisted of 1,027,620 subjects with no history of urticaria. We analyzed cumulative incidences of urticaria, chronic urticaria, and chronic urticaria remission using the life table estimation method from 2004 to 2013. Their association with related factors was analyzed using the Cox proportional hazards analysis. Results: From 2004 to 2013, a total of 49,129 patients with new-onset urticaria were identified. The 10-year cumulative incidence rate of urticaria for the general population was 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8%. Remission rates of chronic urticaria were 52.6% at 1 year and 88.9% at 5 years. Age, sex, residential area, and autoimmune thyroid disease were significantly associated with urticaria or chronic urticaria, but not with chronic urticaria remission, after adjusting for covariates. Female individuals were more likely to have new-onset urticaria but less likely to develop chronic urticaria compared with male individuals. Conclusions: During the 10-year follow-up period, only a small proportion of patients with newonset urticaria developed chronic urticaria. Remission was achieved in the majority of patients with chronic urticaria regardless of demographic characteristics or accompanying thyroid disease.
Introduction
Urticaria is a heterogeneous group of diseases, and the spectrum of clinical manifestations of different urticaria subtypes is extremely wide. 1 Urticaria is classified as either acute or chronic urticaria based on the duration of illness. 2 Both types of urticaria are fundamentally mast cell-driven diseases. 1 Nevertheless, acute urticaria is self-limited and routine diagnostic measures are not recommended. 1 In contrast, chronic urticaria has an unpredictable course, treatable causes are rarely identified, and management is based on controlling clinical symptoms until spontaneous remission. 3 Chronic urticaria, which includes chronic spontaneous urticaria (CSU) and physical urticaria, has a huge influence on quality of life. 4, 5 Moreover, the duration of chronic urticaria varies depending on the subtype and severity. 6e8 Understanding the natural course of urticaria is essential for providing accurate information to patients and for preventing unnecessary anxiety for patients and frustration for physicians. 9 However, published data regarding the natural history of urticaria have some limitations. The majority of previous studies on the natural history of urticaria focused on the duration of CSU. 10e13 Therefore, only fragmentary results of other aspects of the natural course of urticaria exist, and the frequency of progression from acute urticaria to chronic urticaria has not been established. 14 Additionally, previous studies were typically performed in a hospital setting 15 and included specific age groups instead of the general population. 10e12 The National Health Insurance ServiceeNational Sample Cohort (NHIS-NSC) is a population-based cohort established by the National Health Insurance Service (NHIS) in South Korea. In this study, we aimed to investigate the natural course of new-onset urticaria using the NHIS-NSC data.
Methods

Data source
We used the 2002e2013 NHIS-NSC data from the NHIS in South Korea, which is a national representative sample with 1,025,340 individuals in 2002, who were systematically stratified and randomly sampled; the NHIS-NSC represents 2.2% of the Korean population, as an initial cohort, and contains follow-up data until 2013. 16 The initial cohort was restored annually to maintain the representativeness of the data by substituting a representative sample of newborns for follow-up loss due to death or emigration. 16 This study was exempt from the approval of the Institutional Review Board because the data set consisted of deidentified secondary data.
Study population and selection process of patients with urticaria
The selection process for the study is shown in Figure 1 . To define new-onset urticaria, a 2-year washout period (2002e2003) was used in this study. Patients who had at least 1 outpatient visit with any diagnostic codes of urticaria (L50.1, L50.2, L50.3, L50.4, L50.5, L50.8, L50.9, L56.3, or T78.3) of the International Classification of Diseases, tenth revision (ICD-10) in 2002 and 2003 were excluded (n ¼ 55,652). Finally, the study cohort consisted of 1,027,620 subjects with no history of urticaria. They were followed-up during 2004 and 2013. In the study cohort, a patient with urticaria was defined as having at least 2 outpatient visits with a primary diagnostic code of urticaria (L50.1, L50.2, L50.3, L50.4, L50.5, L50.8, L50.9, L56.3, or T78.3) based on the ICD-10 and the prescription of urticaria medicines (H1-antihistamines, systemic steroids, azathioprine, cyclosporine, or methotrexate). We excluded claims without identifiable durations of drug prescriptions that were necessary to define chronic urticaria and chronic urticaria remission.
A patient with chronic urticaria was defined as having continuous management of 42 days. The period from the start date of the urticaria episode to the date when all prescribed urticaria drugs had been used was considered the duration of continuous management. If the patient returned within 7 days from the time when all the prescribed urticaria drugs had been used, this was also considered a visit for continuous management of the same urticaria episode. Chronic urticaria in this study includes both CSU and physical urticaria because a specific ICD-10 code for CSU is lacking. Remission of chronic urticaria was defined if a patient with chronic urticaria never utilized medical services to treat urticaria for 365 days, even after using all the prescribed urticaria medicines.
Statistical analysis
To describe the general characteristics of the study population, the c 2 test was performed using dependent variables, including urticaria, chronic urticaria, and chronic urticaria remission, and independent variables, including sex, age group (0e9, 10e19, 20e44, 45e64, 65 years), residential area, income level, and level of medical institution during the first visit. For urticaria patients, the values of the covariates were those recorded at the first visit for urticaria during the follow-up period. The presence of autoimmune thyroid disease during 2002e2013 was also entered as an independent variable. A patient with autoimmune thyroid disease was defined as a patient with diagnostic codes for Grave's disease (E05.0) and Hashimoto's thyroiditis (E06.3). Annual incidence rates of urticaria per 100,000 person-years were calculated.
Cumulative incidences of urticaria, chronic urticaria, and chronic urticaria remission were calculated using the life table estimation method. 17 Cox proportional hazards analysis was performed to evaluate the association between the dependent and independent variables at baseline. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and SPSS version 24 (IBM, Armonk, NY, USA). All statistical tests were twosided, and P < 0.05 was considered statistically significant.
Results
General characteristics of the study population and incidence of new-onset urticaria
In 2004 and 2013, the NHIS-NSC contained data for 1,027,620 individuals with no history of urticaria (518,757 males and 508,863 females). A total of 49,129 patients were identified as having newonset urticaria ( Table 1 ). The annual incidence rates of urticaria ranged from 45.7 to 82.5 per 100,000 person-years ( Fig. 2 ). The 5year and 10-year cumulative incidence rates of urticaria were 2.1% and 4.9%, respectively ( Fig. 3a) . A significantly greater proportion of women developed new-onset urticaria (5.4% women vs. 4.2% men) ( Table 1 ). However, the female predominance was clearly found only for patients aged 20e44 and 45e64 years ( Table 2) . Moreover, patients aged 10e19 and 20e44 years were less likely to develop urticaria compared with those in other age groups ( Table 1) .
The multivariable Cox regression analysis showed that these variables were significantly associated with urticaria (Table 3) . After adjusting for covariates, the risk of urticaria was significantly higher for females (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.23e1.28) than for males. Patients aged 10e19, 20e44, and 45e64 years had a lower risk of urticaria than those aged 0e9 years. Rural residence was significantly associated with a higher risk of urticaria than urban residence, even after adjusting for income levels and level of medical institutions. Both autoimmune thyroid diseases (Grave's disease and Hashimoto's thyroiditis) were associated with a higher risk of the development of urticaria ( Table 3) .
Development of chronic urticaria among patients with new-onset urticaria
In this study population, among all patients with new-onset urticaria, 2980 patients (6.1%) were finally identified as having chronic urticaria (Table 1) . Therefore, most patients (93.9%) with new-onset urticaria were classified as having acute urticaria (nonchronic urticaria). Of the 2980 patients with chronic urticaria, 1389 patients (46.6%) already had chronic urticaria when they were first diagnosed with urticaria. The remaining 1591 (53.4%) had acute urticaria at their first diagnosis of urticaria, but they subsequently developed chronic urticaria when the disease recurred after an average of 613.6 days (standard deviation, 760.6 days). The 5-year and 10-year cumulative incidence rates of chronic urticaria among all patients with new-onset urticaria were 6.3% and 7.8%, respectively (Fig. 3b ).
The proportion of those who developed chronic urticaria among patients with new-onset urticaria was significantly lower for women than for men (5.6% vs. 6.6%). However, the number of chronic urticaria cases was higher for women than for men (1548 vs. 1432), which could be attributed to the higher number of women with new-onset urticaria (27,510 vs. 21,619). Regarding age groups, patients aged 0e9 years had the lowest proportion of chronic urticaria among those with urticaria ( Table 1) .
The multivariable Cox regression analysis showed that some risk factors for the development of chronic urticaria were almost the opposite of those for new-onset urticaria. Women were at significantly lower risk for the development of chronic urticaria after adjusting for other demographic differences (HR, 0.75; 95% CI, 0.70e0.81) compared with men. Patients aged 0e9 years had a lower risk of chronic urticaria than patients in other age groups. Rural residence was associated with a lower risk of chronic urticaria compared with urban residence after adjusting for covariates. In contrast, both autoimmune thyroid diseases showed similar associations with new-onset urticaria ( Table 3) .
Chronic urticaria remission
Of 2980 patients with chronic urticaria in the study population, 1893 patients experienced remission (63.5%) ( Table 1) .
Approximately 50% of patients with chronic urticaria experienced remission after 11 months. After 3 months, 25.2% of patients with chronic urticaria experienced remission. The remission rates of chronic urticaria were 52.6% at 1 year, 77.7% at 3 years, and 88.9% at 5 years (Fig. 3c ). The multivariable Cox regression analysis found that income level was the only variable that was significantly associated with chronic urticaria remission. The middle to highest income level was significantly associated with higher rates of chronic urticaria remission compared with the lowest income level ( Table 3) .
Discussion
This study investigated the long-term natural course of newonset urticaria using a nationally representative cohort. We showed that the 10-year cumulative incidence rate of urticaria for the general population was 4.9%, whereas that of chronic urticaria among patients with new-onset urticaria was 7.8%. Half of the patients with chronic urticaria achieved remission after 11 months, and approximately 90% achieved remission within 5 years. Age, sex, residential area, and autoimmune thyroid disease were significantly associated with urticaria or chronic urticaria, but not with chronic urticaria remission.
The main advantage of this study was that it was possible to follow the same individuals for up to 10 years. We used a single data source including all age groups to investigate the whole natural course of urticaria (e.g., onset of urticaria, chronic urticaria development, and chronic urticaria remission). Additionally, we used a nationally representative sample, which enabled the analysis of the natural course of urticaria in the unselected general population.
Little is known about the frequency and risk factors of newonset urticaria for progression to chronic urticaria. We estimated that the cumulative incidence of chronic urticaria was 7.8% among patients with new-onset urticaria during the 10-year follow-up period. This finding means that most patients with new-onset urticaria maintain acute urticaria. A retrospective study conducted at a primary dermatology clinic in Japan reported that approximately 85% of patients with acute spontaneous urticaria experienced remission within 1 month and only 7% still had symptoms for 1 year. 18 Our results indicated several clinical factors affecting progression to chronic urticaria: patients aged 10 years or older, male sex, urban residence and autoimmune thyroid disease were associated with a higher risk of progression to chronic urticaria. It has been believed that women are more likely to have urticaria than men. 9 However, recent studies revealed that a female predominance of urticaria is observed only in specific age groups. 10,19e21 Our study also showed a clear female predominance for new-onset urticaria only for those aged 20e44 and 45e64 years. A female predominance of urticaria in specific age groups could be due to estrogen. Estrogen is believed to enhance humoral immunity and antibody synthesis. 1 Experimental data have shown that estradiol could enhance mast cell activation and allergic sensitization in rodent models. 22 Autoimmunity is thought to be a frequent underlying cause of CSU, 23 and chronic urticaria could be related to other autoimmune processes. 24 Thyroid disease is the most frequently investigated disease that is associated with CSU. 24, 25 Similar to previous studies, we also found that autoimmune thyroid disease was associated with a higher risk of urticaria and progression to chronic urticaria. Approximately 90% of patients with chronic urticaria had remission within 5 years, and more than half of the patients with chronic urticaria achieved remission after 1 year. Our study cohort showed a higher remission rate for chronic urticaria compared with previous reports. 6e8, 15 One possible explanation for the higher remission rate of chronic urticaria is that our study included more mild cases that were frequently excluded from the studies conducted at referral hospitals. Disease severity is associated with the duration of chronic urticaria. 6e8 A study conducted at referral outpatient allergy clinics in Israel reported that all patients with mild chronic urticaria had remission within 2 years, whereas moderate to severe chronic urticaria persisted in 59% of patients for up to 2 years. 6 Additionally, patients who controlled their symptoms with OTC antihistamines might have been classified as experiencing remission during this study; therefore, the remission rate of chronic urticaria may have been overestimated in this study. However, the ability to control symptoms with OTC antihistamines indicates that the severity of urticaria had become milder.
Similar to other studies using claims data, this study had some limitations. First, the operational definitions of diseases from claims data were inevitably different from the actual diagnoses of diseases. For example, a physician could claim different diagnostic codes to get a reimbursement for off-label use of medications. Therefore, we used a strict case definition to minimize misclassification of urticaria. We used only the primary diagnostic codes for urticaria and considered prescription data combined with diagnostic codes to define urticaria cases. Some researchers used only diagnostic codes to define urticaria, and some also used secondary diagnostic codes; however, these approaches have a higher risk of misclassification. Second, this study did not distinguish CSU from physical urticaria. It is difficult to define CSU using our data because a specific ICD-10 code for CSU is lacking. Furthermore, two or more different subtypes of urticaria can coexist. 8, 14, 15 Even with physical urticaria, the avoidance of triggers is often not feasible and patients need to continue using medication. Therefore, the natural history of chronic urticaria (including CSU and physical urticaria), not just CSU alone, is also important. Finally, the data used in this study did not include information about disease severity or specific subtypes of urticaria. A few studies have reported the association between disease severity and the natural course of CSU. 6, 8 Despite these limitations, our study showed the long-term natural course of urticaria using a large, nationally representative sample. During the 10-year follow-up period, less than 10% of patients with new-onset urticaria progressed to chronic urticaria, and most patients with chronic urticaria experienced remission within 5 years regardless of age, sex, residential area, or associated thyroid disease. The results of this study could enable physicians to not only provide more accurate information to their patients but also achieve a better understanding of the nature of the disease. 
